Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS
Press Releases
Ractigen Therapeutics  
December 24, 2024

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

NANTONG and SUZHOU, China, Dec. 24, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient

avatar profile Olean Times Herald

Olean Times Herald


Local & Social